| Attribute | TZ2 | Semaglutide |
|---|---|---|
| Receptor target | GIP + incretin pathway (dual agonist) | incretin pathway only (single agonist) |
| CAS Number | 2023788-19-2 | 910463-68-2 |
| Molecular Weight | 4,813.45 g/mol | 4,113.58 g/mol |
| Class | Dual incretin agonist | incretin receptor agonist |
| Research focus | Combined GIP+incretin pathway incretin signaling | incretin pathway incretin signaling |
The core difference. TZ2 is a dual agonist activating both the GIP and incretin receptors, while Semaglutide selectively agonizes the incretin receptor. Research models use the pair to isolate the contribution of GIP-receptor co-activation to metabolic endpoints.
Why they are compared. Because they share the incretin pathway pathway but differ on GIP, they are the standard comparison for studying single- versus dual-incretin mechanisms in metabolic research.
View both compounds
Full mechanism, specifications, and certificates of analysis for each compound.
Frequently asked questions
What is the difference between TZ2 and Semaglutide?
TZ2 is a dual GIP/incretin receptor agonist; Semaglutide is a single incretin receptor agonist. The added GIP-receptor activity is the key research distinction. Both are Research Use Only.
Is TZ2 stronger than Semaglutide?
Research framing only: TZ2 engages an additional receptor (GIP) beyond incretin pathway, which is the focus of comparative metabolic studies. Ethos Bio makes no efficacy or human-use claims.